Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fate Therapeutics (FATE) Assets Average (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Assets Average for 13 consecutive years, with $331.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets Average fell 29.18% year-over-year to $331.3 million, compared with a TTM value of $331.3 million through Dec 2025, down 29.18%, and an annual FY2025 reading of $379.8 million, down 19.78% over the prior year.
  • Assets Average was $331.3 million for Q4 2025 at Fate Therapeutics, down from $357.7 million in the prior quarter.
  • Across five years, Assets Average topped out at $1.0 billion in Q2 2021 and bottomed at $331.3 million in Q4 2025.
  • Average Assets Average over 5 years is $648.6 million, with a median of $585.9 million recorded in 2023.
  • The sharpest move saw Assets Average skyrocketed 167.3% in 2021, then plummeted 30.13% in 2025.
  • Year by year, Assets Average stood at $953.0 million in 2021, then dropped by 23.67% to $727.5 million in 2022, then dropped by 27.83% to $525.0 million in 2023, then decreased by 10.89% to $467.8 million in 2024, then dropped by 29.18% to $331.3 million in 2025.
  • Business Quant data shows Assets Average for FATE at $331.3 million in Q4 2025, $357.7 million in Q3 2025, and $385.2 million in Q2 2025.